About Stage III NSCLC
Testing
Stage III NSCLC is a heterogeneous disease1
Approximately one-fifth of patients with NSCLC present with Stage III disease, and the majority have unresectable tumours2
In Stage III NSCLC, cure is the treatment goal1
THE IASLC STAGING MANUAL IN THORACIC ONCOLOGY, VERSION 8 SUBDIVIDES STAGE III NSCLC INTO IIIA, IIIB AND IIIC PRESENTATIONS3
Testing
NSCLC: Non-Small Cell Lung Cancer; IASLC: International Association for the Study of Lung Cancer;
Which of your patients could
benefit from IMFINZI?
NEXT
IMFINZI helps restore the anti-tumour immune response8
References: 1. Eberhardt W..E , De Ruysscher D, Weder W, et al; 2nd ESMO Consensus Conference in Lung Cancer:locally advanced stage III non-small-cell lung cancer Ann Oncol. 2015;26:1573-1588. 2. Royal College of Physicians UK. National Lung Cancer Audit Annual report 2018. https://www.rcplondon.ac.uk/projects/national-lung-cancer-audit. (Accessed June 2020) 3. Detterbeck FC, Boffa. DJ, Kim. AW, et al; The Eighth Edition Lung Cancer Stage Classification Chest. 2017;151(1):193-203. 4. Postmus PE, Kerr KM, Oudkerk M, et al; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv1-iv21. 5. Curran WJ Jr, Paulus R, Langer CJ, et al; Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410. J Natl Cancer Inst. 2011;103(9):1452-1460. 6. Hanna N, Neubauer M, Yiannoutsos C, et al; Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology J Clin Oncol. 2008;26(35):5755-5760. 7. Auperin A, Pechoux. CL, Rolland. E, et al. Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer J Clin Oncol. 2010;28(13):2181-2190. 8. Stewart R, Morrow M, Hammond SA, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015;3(9):1052-1062.